Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Desvenlafaxine succinate
Drug ID BADD_D00622
Description Desvenlafaxine (O-desmethylvenlafaxine) the major active metabolite of venlafaxine, is an antidepressant from the serotonin norepinephrine reuptake inhibitor (SNRI) class[Label]. Desvenlafaxine may be used to treat major depressive disorder[Label]. It is formulated as an extended release tablet[Label]. Desvenlafaxine was approved by the FDA in 2008[L6016].
Indications and Usage Desvenlafaxine is indicated for the treatment of major depressive disorder in adults[A6990,A6991,Label].
Marketing Status approved; investigational
ATC Code N06AX23
DrugBank ID DB06700
KEGG ID D02570; D11619
MeSH ID D000069468
PubChem ID 9800068
TTD Drug ID D0O3FG
NDC Product Code 16436-0087; 59762-1211; 63629-7559; 68180-593; 68180-604; 68788-7175; 71335-2130; 46708-541; 71335-1331; 59762-1222; 71205-586; 24196-162; 66651-928; 71335-1150; 72189-147; 42816-1211; 46708-542; 0008-1211; 68788-7194; 14501-0065; 42816-1210; 42816-1222; 65841-173; 68724-1236; 69766-008; 0008-1210; 51991-006; 68071-2704; 68180-592; 65977-0142; 0008-1222; 46708-540; 51991-312; 59762-1210; 63629-7525; 53296-0087; 50090-5274; 14778-0606; 51991-311
UNII ZB22ENF0XR
Synonyms Desvenlafaxine Succinate | Succinate, Desvenlafaxine | O-desmethylvenlafaxine Succinate Monohydrate | Monohydrate, O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate Monohydrate | Succinate Monohydrate, O-desmethylvenlafaxine | 2-(1-hydroxycyclohexyl)-2-((4-hydroxyphenyl)ethyl)dimethylammonium 3-carboxypropanoate monohydrate | O-desmethylvenlafaxine Succinate | O desmethylvenlafaxine Succinate | Succinate, O-desmethylvenlafaxine | WY 45,233 | 45,233, WY | WY-45,233 | WY45,233 | WY-45233 | WY45233 | WY 45233 | 45233, WY | Pristiq | Desvenlafaxine | O-desmethylvenlafaxine | O desmethylvenlafaxine | 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol
Chemical Information
Molecular Formula C20H31NO6
CAS Registry Number 448904-47-0
SMILES CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O.C(CC(=O)O)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abnormal dreams17.15.02.001; 19.02.03.001---
Angioedema10.01.05.009; 22.04.02.008; 23.04.01.001---
Anorgasmia19.08.01.001--
Anxiety19.06.02.002--
Asthenia08.01.01.001---
Blood pressure increased13.14.03.005---
Blood prolactin increased13.10.03.002---
Chills08.01.09.001; 15.05.03.016--
Constipation07.02.02.001--
Coronary artery occlusion02.02.01.006; 12.02.01.036; 24.04.04.013---
Dermatitis allergic10.01.03.014; 23.03.04.003---
Diarrhoea07.02.01.001--
Disturbance in attention17.03.03.001; 19.21.02.002--
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.007--
Dry mouth07.06.01.002--
Dysgeusia07.14.03.001; 17.02.07.003--
Ejaculation delayed21.03.01.001---
Ejaculation disorder21.03.01.002--
Ejaculation failure21.03.01.003---
Epistaxis22.04.03.001; 24.07.01.005--
Extrapyramidal disorder17.01.02.007--
Fatigue08.01.01.002--
Feeling jittery08.01.09.016---
Gastrointestinal haemorrhage07.12.02.001; 24.07.02.009---
Hallucination19.10.04.003--
Headache17.14.01.001--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Hypomania19.16.02.001---
Insomnia17.15.03.002; 19.02.01.002--
The 1th Page    1 2 3    Next   Last    Total 3 Pages